Lumida
/OFIX
⌘K
Orthofix Medical Inc

Orthofix Medical Inc

OFIX
$8.93USD+2.76%+0.24 today

MARKET CAP

363.7M

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $9

52W RANGE

$9
$17

AI Summary

Stalk
TrimMedium

The asset remains in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price has been rejected at the 9/20 EMA band repeatedly, reinforcing a medium-term bearish bias. Oversold status does not grant mean-reversion permission, and short-term timing is neutral. Execution should be deferred into future rally attempts into EMA resistance rather than sold immediately. A Trim is recommended to seek a better entry point on a bounce into the EMAs.

  • Q2 EPS of $0.07 beats est; revenue $210.9M (+4% YoY).
  • Global Spine Fixation and Limb Reconstruction segments up double digits.
  • Q2 net loss widened to $15.8M despite revenue gains.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$464.5M$460.7M$746.6M$799.5M$822.3M
YoY %+14.2%-0.8%+62.1%+7.1%+2.9%
P / Sales1.3x0.9x0.6x0.8x0.7x
EV / Sales1.4x1.1x1.0x1.2x1.1x
Gross Profit, Adj.$349.6M$337.2M$486.3M$545.9M$566.0M
YoY %+14.7%-3.5%+44.2%+12.3%+3.7%
Margin %75.3%73.2%65.1%68.3%68.8%
EV / Gross Profit1.9x1.5x1.6x1.8x1.6x
EBITDA, Adj.$38.9M$8.3M$-71.3M$-222,000$23.2M
YoY %+63.5%-78.5%-954.1%+99.7%+10533.3%
Margin %8.4%1.8%-9.5%-0.0%2.8%
EV / EBITDA17.1x59.8x-10.9x-4381.7x39.7x
EBIT$-8.3M$-13.3M$-139.1M$-84.6M$-81.4M
YoY %-32.7%-59.6%-948.5%+39.2%+3.8%
Margin %-1.8%-2.9%-18.6%-10.6%-9.9%
EV / EBIT-79.9x-37.6x-5.6x-11.5x-11.3x
Net Income$-38.4M$-19.7M$-151.4M$-126.0M$-92.2M
YoY %-1624.8%+48.5%-666.6%+16.8%+26.8%
Net Margin-8.3%-4.3%-20.3%-15.8%-11.2%
EPS (GAAP)-$1.95-$0.98-$4.12-$3.30-$2.33
YoY %-1600.0%+49.7%-320.4%+19.9%+29.4%